Technology
DeepNeo
At the core of our cancer vaccine platform lies the DeepNeo system — a suite of AI solutions including DeepNeo-MHC, DeepNeo-TCR, and DeepNeo-BCR. Going beyond simple MHC binding prediction, DeepNeo identifies neoantigens capable of activating both T cells and B cells. Through this systematic approach, DeepNeo is evolving into the world’s most advanced AI system for designing optimal vaccines to fight cancer.
- Our proprietary AI system, DeepNeo, discovers tumor-specific neoantigens with verified immunogenicity and designs mRNA or peptide-based therapeutic vaccines targeting these antigens.
- The DeepNeo system consists of the DeepNeo-MHC/TCR module, which predicts MHC binding affinity and T-cell reactivity, and the DeepNeo-BCR module, which predicts B-cell reactivity.
- Aiming to identify true neoantigens, the DeepNeo system offers cost-efficient and highly accurate neoantigen prediction compared to existing algorithms, showing particularly improved performance in predicting MHC class II binding and B-cell reactivity.
